HIM
CSTL icon

Hillsdale Investment Management’s Castle Biosciences CSTL Stock Holding History

Hillsdale Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-260
Closed -$7.42K – 599
2024
Q3 		$7.42K Sell
260
-40
-13% -$1.02K ﹤0.01% 521
2024
Q2 		$6.53K Hold
300
– – ﹤0.01% 520
2024
Q1 		$6.64K Buy
+300
New +$6.53K ﹤0.01% 517
2020
Q2 		– Sell
-9,400
Closed -$281K – 592
2020
Q1 		$281K Buy
+9,400
New +$284K 0.03% 386

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Hillsdale Investment Management's CSTL Position: Q4 2024 in Review

Hillsdale Investment Management sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 260 shares — an estimated $7.42K sold.

Hillsdale Investment Management first reported a position in CSTL in Q1 2020 and held it in 4 quarters. The position peaked at $281K in Q1 2020. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

  • Hillsdale Investment Management reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 260 Castle Biosciences shares in Q4 2024, an estimated $7.42K.
  • Hillsdale Investment Management first reported a position in Castle Biosciences in Q1 2020 and held it in 4 quarters.
  • Hillsdale Investment Management's Castle Biosciences position peaked at $281K in Q1 2020.
  • 197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Hillsdale Investment Management's 13F filing for Q4 2024, filed 11 Feb 2025.